FDA approves multi-dose tirzepatide vials for both brands

The U.S. Food and Drug Administration approved a new way to package tirzepatide on January 7, 2026, clearing a "multiple-dose single-patient use vial" for both Eli Lilly brands: Zepbound under supplement NDA 217806/S-037 and Mounjaro under supplement NDA 215866/S-041 ^[1][2]. Both approval letters were signed the same afternoon by John Sharretts, MD, director of FDA's Division of Diabetes, Lipid Disorders, and Obesity ^[1][2].

Lilly filed both supplemental new drug applications on July 31, 2025 ^[1][2]. Each supplement covers revisions to the Prescribing Information and Medication Guide, plus new carton and container labeling and a new Instructions for Use document specifically for the multi-dose vial ^[1][2]. The existing presentations were not withdrawn: the Zepbound letter lists the single-dose vial Instructions for Use previously approved March 28, 2024, and the single-dose pen version previously approved November 8, 2023, as still part of the labeling package ^[1]. The Mounjaro letter similarly carries forward its single-dose pen instructions from May 13, 2022, and a Quick Reference Guide from the same date ^[2].

What the new vial holds

The current Zepbound label describes the multi-dose vial as a 2.4 mL presentation that contains four weekly 0.6 mL doses, in all six tirzepatide strengths: 10 mg/2.4 mL (4.17 mg/mL) for four 2.5 mg doses, 20 mg/2.4 mL (8.33 mg/mL) for four 5 mg doses, 30 mg/2.4 mL (12.5 mg/mL) for four 7.5 mg doses, 40 mg/2.4 mL (16.7 mg/mL) for four 10 mg doses, 50 mg/2.4 mL (20.8 mg/mL) for four 12.5 mg doses, and 60 mg/2.4 mL (25 mg/mL) for four 15 mg doses ^[3]. That is a different concentration and a different injection volume than the older presentations, which deliver each dose in 0.5 mL from a single-dose pen or single-dose vial ^[3].

The label groups the multi-dose vial with the single-patient-use KwikPen in its Dosage Forms and Strengths section ^[3]. The approval letters describe the vial as single-patient-use, and the Zepbound label added a January 2026 warning that a KwikPen should never be shared between patients, even if the pen needle is changed ^[1][3]. The recommended dosing itself did not change: the label still calls for a 2.5 mg starting dose once weekly for four weeks, increases in 2.5 mg steps after at least four weeks, and a maximum of 15 mg weekly ^[3].

Because the supplements added a presentation rather than a new active ingredient, indication, dosage form, dosing regimen, or route of administration, FDA said Lilly was exempt from the pediatric assessment requirement under the Pediatric Research Equity Act ^[1][2].

Why it matters for patients

A four-dose vial is a different handling experience than a prefilled pen. Doses are measured and drawn up by the user rather than dialed or fixed, and the vial is intended for one person only ^[1][2][3]. That means the new Instructions for Use document matters: it is the label section that spells out how to use this presentation, and FDA required Lilly to publish the full content of labeling within 14 days of the January 7 letter ^[1][2].

The approval also signals more supply options in the tirzepatide market, since the same six strengths are now available in single-dose pens, single-dose vials, KwikPens, and multi-dose vials ^[3]. What the sources do not say: the price of the multi-dose vials, when or where they would be stocked, whether syringes and needles are supplied with them, or whether insurers will cover one presentation over another. Those details are not addressed in the approval letters or the label excerpt.

What happens next

FDA gave Lilly 14 days from January 7, 2026, to submit structured product labeling, and up to 30 days after printing to submit final printed carton and container labeling ^[1][2]. A later Mounjaro approval, dated August 27, 2026, for supplements S-044 and S-045, lists the multi-dose vial Instructions for Use as "previously approved January 7, 2026," confirming the presentation remained part of the Mounjaro labeling through that update ^[4].